Jade Biosciences (JBIO) risk factors, FY2024 10-K

Risks Related to the Merger

1. 01Failure to complete, or delays in completing, the potential Merger with Jade, announced on October 31, 2024, could materially and adversely affect our or Jade’s results of operations, business, financial results and may cause a decline in the market price of our common stock
2. 02We may not be successful in consummating the Merger
3. 03Although there can be no assurance that the Merger will be completed, the negotiation and consummation of the Merger will require significant time on the part of our management, and the diversion of management’s attention may disrupt our business
4. 04Any of the foregoing risks could have a material adverse effect on our business, financial condition and prospects
5. 05Failure to complete the Merger may result in either Jade or us paying a termination fee to the other party, and could harm our common stock price and future business and operations of each company
6. 06If the conditions to the Merger are not satisfied or waived, the Merger may not occur
7. 07We and Jade may mutually agree to waive the condition to the Merger requiring approval for listing on Nasdaq, and if such condition is waived, the combined company’s stock may not be listed on Nasdaq following completion of the Merger
8. 08The Merger may be completed even though a material adverse effect may result from the announcement of the Merger, industry-wide changes or other causes
9. 09If we and Jade complete the Merger, the combined company will need to raise additional capital by issuing equity securities or additional debt or through licensing arrangements, which may cause significant dilution to the combined company’s stockholders or restrict the combined company’s operations
10. 10Some of Jade’s and our directors and executive officers have interests in the Merger that are different from our other stockholders
11. 11Our stockholders and Jade stockholders may not realize a benefit from the Merger commensurate with the ownership dilution they will experience in connection with the Merger, including the conversion of Jade common stock issued in the Jade Pre-Closing Financing
12. 12If the Merger is not completed, our stock price may decline significantly
13. 13Our securityholders and Jade securityholders will generally have a reduced ownership and voting interest in, and will exercise less influence over the management of, the combined company following the completion of the Merger as compared to their current ownership and voting interests in the respective companies
14. 14During the pendency of the Merger, we and Jade may not be able to enter into a business combination with another party on more favorable terms because of restrictions in the Merger Agreement, which could adversely affect their respective business prospects
15. 15Certain provisions of the Merger Agreement may discourage third parties from submitting competing proposals, including proposals that may be superior to the transactions contemplated by the Merger Agreement
16. 16Lawsuits may be filed against us, Jade, or any of the members of our or Jade’s boards of directors arising out of the Merger, which may delay or prevent the Merger
17. 17Our ability to consummate the Merger depends on our ability to retain the employees required to consummate such transaction
18. 1892% of our workforce was terminated as of December 31, 2024. Our cash conservation activities may yield unintended consequences, such as attrition beyond our Workforce Reduction Plan and reduced employee morale, which may cause remaining employees to seek alternative employment
19. 19Our cash preservation activities, including the Workforce Reduction Plan, may not result in anticipated savings, could result in total costs and expenses that are greater than expected and could disrupt our business
20. 20We may become involved in litigation, including securities class action litigation, that could divert management’s attention and harm our business, and insurance coverage may not be sufficient to cover all costs and damages

Risks Related to Our Limited Operating History, Financial Position and Capital Requirements

1. 21We are a biopharmaceutical company with a limited operating history
2. 22We have incurred significant operating losses since our inception and anticipate that we will continue to incur losses for the foreseeable future. We may never achieve or maintain profitability
3. 23We have no products approved for commercial sale and have not generated any revenue from product sales
4. 24Since our inception, we have invested substantially all of our efforts and financial resources in the development of AV-101 to address the core disease processes of PAH. We do not intend to resume development of AV-101 or conduct research on additional product candidates at this time

Risks Related to the Research and Development Activities

1. 25The results of earlier studies and trials may not be predictive of future trial results
2. 26Interim, topline and preliminary results from our preclinical studies and clinical trials that we announce or publish from time to time may change as more data become available and are subject to audit and verification procedures that could result in material changes in the final data

Risks Related to Our Intellectual Property

1. 27applications or to maintain, defend and enforce any patents that may issue from such patent applications at a reasonable cost or in a timely manner. It is also possible that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection
2. 28Intellectual property litigation could cause us to spend substantial resources and prevent us from pursuing our programs
3. 29Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual property rights against third parties
4. 30Third parties may initiate or threaten legal proceedings alleging that we are infringing their intellectual property rights, the outcome of which would be uncertain and could have a material adverse effect on the success of our business
5. 31If we do not obtain additional protection under the Hatch-Waxman Amendments and similar foreign legislation cannot be obtained to extend the patent protection for a product candidate, business operations may be materially harmed
6. 32We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or expiration of a third-party patent which might adversely affect our ability to develop, manufacture and market our product candidate
7. 33Changes in patent law could diminish the value of patents in general, thereby impairing the ability to protect product candidates
8. 34There may be significant pressure on the U.S. government and international governmental bodies to limit the scope of patent protection both inside and outside the United States for disease treatments that prove successful, as a matter of public policy regarding worldwide health concerns
9. 35Obtaining and maintaining patent protection depends on compliance with various procedural, document submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for non-compliance with these requirements
10. 36We may be subject to claims challenging the inventorship or ownership of our patents and other intellectual property
11. 37We may be subject to claims that our employees, consultants or independent contractors have wrongfully used or disclosed confidential information of third parties
12. 38If we are unable to protect the confidentiality of our trade secrets, our business and competitive position would be harmed
13. 39If we and our partners do not adequately protect the trademarks and trade names for our products, then we and our partners may not be able to build name recognition in our markets of interest and our business may be adversely affected

Risks Related to Government Regulation

1. 40We may be unable to obtain regulatory approval under applicable regulatory requirements. The denial or delay of any such approval would delay commercialization of any product candidates and adversely impact our potential to generate revenue, our business and our results of operations
2. 41Of the large number of pharmaceutical products in development, only a small percentage successfully complete the FDA or other regulatory bodies’ approval processes and are commercialized
3. 42Should we in the future conduct clinical trials outside the United States, and the FDA, EMA and applicable foreign regulatory authorities may not accept data from such trials
4. 43also must submit new or supplemental applications and obtain approval for certain changes to product labeling, or manufacturing process
5. 44We have received orphan drug designation from the FDA and EMA for AV-101 for treatment of PAH, but we may be unable to obtain additional designations or to maintain the benefits associated with orphan drug status, including the potential for non-patent market exclusivity
6. 45Even if FDA approval is obtained in the United States, it does not guarantee approval for or successful commercialization of a product candidate outside of the United States, which would limit the ability to realize its full market potential
7. 46Our business operations and relationships with investigators, healthcare professionals, consultants, third-party payors, patient organizations and customers have been subject to applicable healthcare regulatory laws, which could expose us to penalties
8. 47Healthcare legislative reform measures may have a material adverse effect on our business and results of operations

Risks Related to Employee Matters

1. 48Our insurance policies may be inadequate and potentially expose us to unrecoverable risks
2. 49laws), federal, and international law and may cause a material adverse impact to our reputation, affect our ability to conduct new studies and potentially disrupt our business

Risks Related to Ownership of Our Common Stock

1. 50Our ability to utilize our net operating loss carryforwards and certain other tax attributes may be limited
2. 51Changes in tax law may adversely affect us or our investors
3. 52Anti-takeover provisions in our charter documents and under Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove our current management
4. 53Our amended and restated bylaws designate certain courts as the sole and exclusive forum for certain types of actions and proceedings that may be initiated by our stockholders, which could limit our stockholders’ ability to obtain a favorable judicial forum for disputes with us or our directors, officers, or employees
5. 54Unfavorable global economic or political conditions could adversely affect our business, financial condition or results of operations
6. 55raise additional capital as needed on acceptable terms, if at all. Any of the foregoing could harm our business and we cannot anticipate all of the ways in which the political or economic climate and financial market conditions could adversely impact our business
7. 56Our business is affected by macroeconomic conditions, including rising inflation, interest rates and supply chain constraints
8. 57Actual or perceived failures to comply with United States and foreign privacy and data protection laws, regulations and standards may adversely affect our business, operations and financial performance
9. 58We may not pay any cash dividends on our capital stock in the foreseeable future, other than the Cash Dividend in connection with the Merger, and capital appreciation, if any, will be our stockholders’ sole source of gain
10. 59We incur increased costs as a result of operating as a public company, and our management is required to devote substantial time to new compliance initiatives
11. 60If we fail to establish and maintain proper and effective internal control over financial reporting, our operating results and our ability to operate our business could be harmed
12. 61Our disclosure controls and procedures may not prevent or detect all errors or acts of fraud
13. 62If securities analysts do not publish research or reports about our business or if they publish negative evaluations of our stock, the price of our stock could decline